Literature DB >> 35589919

The role of non-coding RNAs in neuroinflammatory process in multiple sclerosis.

Anna Nowak1,2, Zofia Wicik1, Marta Wolska1,2, Andleeb Shahzadi3, Piotr Szwed1, Joanna Jarosz-Popek1,2, Jeffrey Palatini4, Marek Postula1, Anna Czlonkowska1,5, Dagmara Mirowska-Guzel1, Ceren Eyileten6,7.   

Abstract

Multiple sclerosis (MS) is a central nervous system chronic neuroinflammatory disease followed by neurodegeneration. The diagnosis is based on clinical presentation, cerebrospinal fluid testing and magnetic resonance imagining. There is still a lack of a diagnostic blood-based biomarker for MS. Due to the cost and difficulty of diagnosis, new and more easily accessible methods are being sought. New biomarkers should also allow for early diagnosis. Additionally, the treatment of MS should lead to the personalization of the therapy. MicroRNAs (miRNAs) and long non-coding RNAs (lncRNAs) as well as their target genes participate in pathophysiology processes in MS. Although the detailed mechanism of action of non-coding RNAs (ncRNAs, including miRNAs and lncRNAs) on neuroinflammation in MS has not been fully explained, several studies were conducted aiming to analyse their impact in MS. In this article, we review up-to-date knowledge on the latest research concerning the ncRNAs in MS and evaluate their role in neuroinflammation. We also point out the most promising ncRNAs which may be promising in MS as diagnostic and prognostic biomarkers.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  Long intergenic non-coding RNAs; Novel biomarker; lincRNA; lncRNA; miRNA; microRNA

Mesh:

Substances:

Year:  2022        PMID: 35589919     DOI: 10.1007/s12035-022-02854-y

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.682


  44 in total

Review 1.  Long Non-coding RNAs as Promising Therapeutic Approach in Ischemic Stroke: a Comprehensive Review.

Authors:  Marta Wolska; Joanna Jarosz-Popek; Eva Junger; Zofia Wicik; Tahmina Porshoor; Lucia Sharif; Pamela Czajka; Marek Postula; Dagmara Mirowska-Guzel; Anna Czlonkowska; Ceren Eyileten
Journal:  Mol Neurobiol       Date:  2020-11-24       Impact factor: 5.590

Review 2.  Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria.

Authors:  Alan J Thompson; Brenda L Banwell; Frederik Barkhof; William M Carroll; Timothy Coetzee; Giancarlo Comi; Jorge Correale; Franz Fazekas; Massimo Filippi; Mark S Freedman; Kazuo Fujihara; Steven L Galetta; Hans Peter Hartung; Ludwig Kappos; Fred D Lublin; Ruth Ann Marrie; Aaron E Miller; David H Miller; Xavier Montalban; Ellen M Mowry; Per Soelberg Sorensen; Mar Tintoré; Anthony L Traboulsee; Maria Trojano; Bernard M J Uitdehaag; Sandra Vukusic; Emmanuelle Waubant; Brian G Weinshenker; Stephen C Reingold; Jeffrey A Cohen
Journal:  Lancet Neurol       Date:  2017-12-21       Impact factor: 44.182

Review 3.  MicroRNAs and Long Noncoding RNAs in Coronary Artery Disease: New and Potential Therapeutic Targets.

Authors:  Lukasz Zareba; Alex Fitas; Marta Wolska; Eva Junger; Ceren Eyileten; Zofia Wicik; Salvatore De Rosa; Jolanta M Siller-Matula; Marek Postula
Journal:  Cardiol Clin       Date:  2020-09-17       Impact factor: 2.213

Review 4.  MicroRNAs fingerprint of bicuspid aortic valve.

Authors:  Jolanda Sabatino; Zofia Wicik; Salvatore De Rosa; Ceren Eyileten; Daniel Jakubik; Carmen Spaccarotella; Annalisa Mongiardo; Marek Postula; Ciro Indolfi
Journal:  J Mol Cell Cardiol       Date:  2019-07-03       Impact factor: 5.000

5.  BC200 RNA in normal human neocortex, non-Alzheimer dementia (NAD), and senile dementia of the Alzheimer type (AD).

Authors:  W J Lukiw; P Handley; L Wong; D R Crapper McLachlan
Journal:  Neurochem Res       Date:  1992-06       Impact factor: 3.996

6.  Comprehensive evaluation of serum microRNAs as biomarkers in multiple sclerosis.

Authors:  Keren Regev; Anu Paul; Brian Healy; Felipe von Glenn; Camilo Diaz-Cruz; Taha Gholipour; Maria Antonietta Mazzola; Radhika Raheja; Parham Nejad; Bonnie I Glanz; Pia Kivisakk; Tanuja Chitnis; Howard L Weiner; Roopali Gandhi
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-08-23

7.  Analysis of miRNA signatures in CSF identifies upregulation of miR-21 and miR-146a/b in patients with multiple sclerosis and active lesions.

Authors:  María Muñoz-San Martín; Gemma Reverter; Rene Robles-Cedeño; Maria Buxò; Francisco José Ortega; Imma Gómez; Jordi Tomàs-Roig; Naiara Celarain; Luisa María Villar; Hector Perkal; José Manuel Fernández-Real; Ester Quintana; Lluís Ramió-Torrentà
Journal:  J Neuroinflammation       Date:  2019-11-14       Impact factor: 8.322

Review 8.  Significance of circulating microRNAs in diabetes mellitus type 2 and platelet reactivity: bioinformatic analysis and review.

Authors:  Justyna Pordzik; Daniel Jakubik; Joanna Jarosz-Popek; Zofia Wicik; Ceren Eyileten; Salvatore De Rosa; Ciro Indolfi; Jolanta M Siller-Matula; Pamela Czajka; Marek Postula
Journal:  Cardiovasc Diabetol       Date:  2019-08-30       Impact factor: 9.951

9.  Circulating miR-150 in CSF is a novel candidate biomarker for multiple sclerosis.

Authors:  Petra Bergman; Eliane Piket; Mohsen Khademi; Tojo James; Lou Brundin; Tomas Olsson; Fredrik Piehl; Maja Jagodic
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2016-04-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.